The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
A minimum of 40 eligible participants will be identified for study participation from the TrialNet Pathway to Prevention study. Participants must have a relative with type 1 diabetes and be positive for insulin autoantibodies and at least one other autoantibody. All participants will receive active treatment of recombinant insulin treatment in capsules of either 67.5 mg daily or 500mg every other week. Participants will need to visit the study site up to eleven times over one year for blood tests and other study procedures. During the beginning treatment phase there are two visits one month apart for those given the 67.5 mg dose, and three visits two weeks apart to titrate the dose for those in the 500mg treatment group. There are three additional treatment visits at months 2, 3, and 6 and 4 additional visits for follow-up at months 7, 8, 9 and 12. The primary outcome is the change in immune function as assessed by change in level or quality of T lymphocyte or autoantibody biomarkers measured between 13 and 26 weeks compared to baseline. .
Type 1 Diabetesoral insulinInsulin, Globin ZincInsulinMethamphetamine
You can join if…
Open to people ages 3–45
Participants in TrialNet Natural History/Pathway to Prevention Study (TN01); is relative of proband with type 1 diabetes
Between ages 3-45 with normal Oral Glucose Tolerance Test (OGTT) or between ages 3-7 with an abnormal OGTT
Confirmed positive for insulin autoantibodies within previous six months
Confirmed positive for one or more other autoantibodies on two separate occasions within the past six months
You CAN'T join if...
Diagnosed with type 1 diabetes
History of treatment with insulin or oral hypoglycemic agent
History of therapy with immunosuppressive drugs or non-physiologic glucocorticoids within the past two years for a period of more than three months
Ongoing use of medications known to influence glucose tolerance
Pregnant or intending to become pregnant while on study or lactating
University of California - San Francisco San Francisco, California, 94158-2549, United States
Stanford University Stanford, California, 94305, United States
in progress, not accepting new patients
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)